Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,689 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal saline solution Clear all
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 28, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Cleft Lip Scarring After Botox

NCT07880860
View directory record Official record
Conditions
Cleft Lip, Cleft Lip Scar
Interventions
Botulinum Toxin Type A (BOTOX) Injection, Normal Saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
0 Days to 12 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Withdrawn Phase 3 Interventional

Tranexamic Acid (TXA) in Hip Arthroscopy

NCT05710146
View directory record Official record
Conditions
Hip Pain Chronic, Hip Impingement Syndrome, Hip Injuries, Blood Loss, Femoro Acetabular Impingement
Interventions
Tranexamic acid, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
CDX-0159, Normal Saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Oral Versus Intravenous Sedation for Ocular Procedures

NCT03246724
View directory record Official record
Conditions
Surgery, Sedation
Interventions
Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 4 Interventional

Low Dose Ketamine and Acute Pain Crisis

NCT04330183
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 28, 2026, 10:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

NCT06059690
View directory record Official record
Conditions
Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
Interventions
pH Measurement of in vivo tissue
Diagnostic Test
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Suppression of Toll Like Receptors by Insulin

NCT01151605
View directory record Official record
Conditions
Insulin Resistance
Interventions
insulin infusion, Dextrose infusion, Saline Infusion
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Not listed Not applicable Interventional

Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time

NCT02620501
View directory record Official record
Conditions
Dysphagia, GERD, Abdominal Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 28, 2026, 10:45 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis

NCT04740294
View directory record Official record
Conditions
Bronchiolitis, Viral
Interventions
Magnesium Sulfate
Drug
Lead sponsor
University of Louisville
Other
Eligibility
1 Month to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars

NCT03935594
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
PRP Injection, Saline Injection
Biological · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Ridge Preservation With FDBA (Freeze Dried Bone Allograft) Using Dexamethasone vs. Saline

NCT06556095
View directory record Official record
Conditions
Bone Graft, Tooth Extraction
Interventions
Dexamethasone 4mg/ml solution
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Recruiting Not applicable Interventional

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

NCT07225205
View directory record Official record
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions
Intravenous fluids, ERAS
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06375512
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ Vaccine (IN001), Placebo, Shingrix
Biological
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Industry
Eligibility
50 Years to 69 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

NCT04078022
View directory record Official record
Conditions
Shigella
Interventions
SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management

NCT03001453
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal Bupivacaine, 0.25% Bupivacaine with epinephrine, Saline
Drug
Lead sponsor
American Hip Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Hinsdale, Illinois • Westmont, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

NCT03359239
View directory record Official record
Conditions
Urothelial/Bladder Cancer, Nos
Interventions
Atezolizumab, PGV001, Poly ICLC, Normal saline
Drug · Biological
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

NCT01473264
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
recombinant human CC10 (rhCC10), placebo
Drug
Lead sponsor
Clarassance, Inc.
Industry
Eligibility
24 Weeks to 29 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 28, 2026, 10:45 PM EDT
Terminated Phase 3 Interventional Results available

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

NCT02722304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions
ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 4 Interventional

A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery

NCT02233400
View directory record Official record
Conditions
Hospital Costs, Length of Stay, Postoperative Pain Score, Patient Satisfaction
Interventions
Acetaminophen
Drug
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Allentown, Pennsylvania • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Naloxone for Optimizing Hypoxemia Of Lung Donors

NCT02581111
View directory record Official record
Conditions
Brain Death, Organ Donors, Lung Transplantation
Interventions
Naloxone, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
13 Years to 70 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Denver, Colorado • Metairie, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Not applicable Interventional

EPIC: Effect of Povidone Iodine Periurethral Cleansing on Level of Contamination With Clean Catch

NCT03933436
View directory record Official record
Conditions
Urine Contamination
Interventions
Iodine swabs., Saline flush.
Other
Lead sponsor
Travis Callahan
Federal
Eligibility
28 Days to 12 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 28, 2026, 10:45 PM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 28, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Vitamin C in the Critically Ill Patient

NCT01587963
View directory record Official record
Conditions
Shock
Interventions
Ascorbic Acid, Ringers Lactate or Normal Saline
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 28, 2026, 10:45 PM EDT